Pharmacyte Biotech Inc (OTCMKTS:PMCB) stated that it has completed the interim audit of cGMP facility. The company will acquire the cell-in-a-box capsules for the clinical trials from the same facility. Austrianova’s Chief Technical Officer, Professor Walter H. Günzburg, stated that they are pleased to report that there were no major issues during the inspection process.
The company will now carry out the “shake-down” runs at the cGMP facility. These tests are needed before the facility can commence production work of the three consecutive runs that will be utilized to validate compliance of the process as per cGMP standards.
In the last trading session, the share price of Pharmacyte plunged over 5% to close the day at $.0910.
Nutra Pharma Corp. (OTCMKTS:NPHC) Obtains Orphan Drug Status For RPI-78M
Nutra Pharma Corp. (OTCMKTS:NPHC) reported that they have obtained Orphan Drug status from the FDA for its drug candidate RPI-78M for the cure of Multiple Sclerosis in children. Rik J. Deitsch, the CEO and Chairman, said that obtaining orphan drug status by the U.S. FDA is a considerable milestone for the company. Multiple Sclerosis in children is an important disease segment that as of now is not being treated by other drug candidates in the market.
Based on open label trials and pre-clinical trials using RPI-78M, the management believes that drug has the ability to get through the approval process. Now, they intend to prepare an Investigative NDA with the FDA and advance the clinical trial protocols required for drug approval.
Growblox Sciences Inc (OTCMKTS:GBLX) Appoints Sandra Tiffany as New General Manager
Growblox Sciences Inc (OTCMKTS:GBLX) reported that they have appointed Sandra Tiffany as new General Manager. Ms. Tiffany has served as a Nevada State Senator for as much as 14 years. During this period, she served on various leadership roles and authored “game changing” legislation.
